Organ Transplant MedTech TransMedics Q3 Performance Disappoints, Analyst Outlines Investor Worries - TransMedics Gr ( NASDAQ:TMDX )
TransMedics Group Inc TMDX stock is trading lower on Tuesday. The organ transplant medtech company reported a third-quarter EPS of $0.12, missing the consensus of $0.30. It reported sales of $108.8 million, up 64% year over year, but it missed the consensus of $115 million.
| Ticker |
Sentiment |
Impact |
|
CCORF
|
Neutral
|
8 %
|
|
TMDX
|
Somewhat Bullish
|
66 %
|
